ELVN Stock Price | Enliven Therapeutics Inc. P/E, Revenue, EPS, & Forecasts

Enliven Therapeutics Inc. • ELVN

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Enliven Therapeutics Inc.

Ticker

ELVN

Trading on

NASDAQ

ISIN

US29337E1029

Industry

Biotechnology

Sector

Healthcare

CEO

Samuel S. Kintz M.B.A.

Headquarters

6200 Lookout Road, Boulder, CO, United States, 80301

Employees

Website

enliventherapeutics.com

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Metrics

BasicAdvanced

Market cap

$1.27B

P/E ratio

EPS

-$1.81

Dividend Yield

0.00%

Beta

1.07

Forward P/E ratio

EBIDTA

$-112M

Ex dividend date

Price & volume

Market cap

$1.27B

Average daily volume

0.5M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

2.56

Earnings

EPS

-$1.81

EPS estimate (current quarter)

-$0.47

EPS estimate (next quarter)

-$0.49

EBITDA

$-112M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.07

52-week High

$25.67

52-week Low

$13.30

50-day moving average

$20.73

200-day moving average

$20.03

Short ratio

13.74

Short %

18.69%

Management effectiveness

ROE (TTM)

-25.43%

ROA (TTM)

-17.62%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

59.3M

Float

37.3M

Insiders %

8.21%

Institutions %

102.78%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 8 analysts.

Average price target

$41.38

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.46

-$0.52

11.11%

Q4 • 24Beat

-$0.57

-$0.50

-13.03%

Q1 • 25Missed

-$0.49

-$0.55

10.91%

Q2 • 25Beat

-$0.32

-$0.50

36.00%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-25.3M

-∞%

Q2 • 25

$0M

$-20.1M

-∞%

Q3 • 25

NaN%

-20.47%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$504M

$15.4M

3.06%

Q2 • 25

$491M

$14.8M

3.01%

Q3 • 25

-2.58%

-4.29%

-1.76%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-17.1M

$-184M

$218M

$-17.2M

Q2 • 25

$-13.3M

$-4.1M

$-0.4M

$-13.3M

Q3 • 25

-22.15%

-97.79%

-100.17%

-22.78%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Enliven Therapeutics Inc. share?

Enliven Therapeutics Inc. shares are currently traded for undefined per share.

How many shares does Enliven Therapeutics Inc. have?

Enliven Therapeutics Inc. currently has 59.3M shares.

Does Enliven Therapeutics Inc. pay dividends?

No, Enliven Therapeutics Inc. doesn't pay dividends.

What is Enliven Therapeutics Inc. 52 week high?

Enliven Therapeutics Inc. 52 week high is $25.67.

What is Enliven Therapeutics Inc. 52 week low?

Enliven Therapeutics Inc. 52 week low is $13.30.

What is the 200-day moving average of Enliven Therapeutics Inc.?

Enliven Therapeutics Inc. 200-day moving average is $20.03.

Who is Enliven Therapeutics Inc. CEO?

The CEO of Enliven Therapeutics Inc. is Samuel S. Kintz M.B.A..

How many employees Enliven Therapeutics Inc. has?

Enliven Therapeutics Inc. has 65 employees.

What is the market cap of Enliven Therapeutics Inc.?

The market cap of Enliven Therapeutics Inc. is $1.27B.

What is the P/E of Enliven Therapeutics Inc.?

The current P/E of Enliven Therapeutics Inc. is null.

What is the EPS of Enliven Therapeutics Inc.?

The EPS of Enliven Therapeutics Inc. is -$1.81.

What is the PEG Ratio of Enliven Therapeutics Inc.?

The PEG Ratio of Enliven Therapeutics Inc. is null.

What do analysts say about Enliven Therapeutics Inc.?

According to the analysts Enliven Therapeutics Inc. is considered a buy.